Tuesday, September 08, 2020 2:35:51 PM
Evofem Biosciences Announces U.S. Commercial Launch of Phexxi™ (lactic acid, citric acid and potassium bitartrate), the Fir...
September 08 2020 - 08:30AM
SAN DIEGO, Sept. 8, 2020 /PRNewswire/ -- Evofem Biosciences, Inc. (NASDAQ: EVFM) today announced that Phexxi™ (lactic acid, citric acid and potassium bitartrate), the first and only non-hormonal prescription vaginal gel is now available in the United States for the prevention of pregnancy in females of reproductive potential for use as an on-demand method of contraception.
(PRNewsfoto/Evofem Biosciences, Inc.)
Approved by the U.S. Food and Drug Administration (FDA) on May 22, 2020, Phexxi is a vaginal pH modulator designed to maintain vaginal pH within the normal range of 3.5 to 4.5 – an acidic environment that is inhospitable to sperm. Phexxi will be commercially available in a box containing 12 individually wrapped Phexxi applicators. For more information, visit www.phexxi.com.
"As a leader of innovation in women's healthcare, we are thrilled to usher in a new era of sexual and reproductive health with the launch of Phexxi," said Saundra Pelletier, Evofem Biosciences' Chief Executive Officer. "Millions of women have either settled for less or completely opted out of using birth control because they have had enough with side effects and lack of control. Today, we are fulfilling Evofem's mission of delivering a novel contraceptive option that women have been waiting for."
Evofem is also launching the Phexxi Concierge Experience, a comprehensive woman-centric telemedicine support system to help ensure Phexxi is accessible to all women who need it. This robust offering of services is designed to help women quickly consult with a healthcare provider to secure a Phexxi prescription, determine their insurance coverage and/or out-of-pocket costs, receive counseling support and refill reminders, and fill their prescription through their local neighborhood pharmacy or our mail order pharmacy partner, KnippeRx, that is expected to deliver Phexxi right to their door.
Evofem is committed to facilitating access to Phexxi for women who are not covered by government or private health plans and will provide a financial assistance program to enable access to Phexxi for eligible women. Through this program, eligible patients may pay a $0 co-pay for their first prescription of Phexxi, and as little as $30 on future prescriptions.
ABOUT PHEXXI™ (lactic acid, citric acid and potassium bitartrate) VAGINAL GEL 1.8%, 1%, 0.4%
Phexxi is a prescription vaginal gel used to prevent pregnancy in females who choose to use an on-demand method of birth control.
LIMITATIONS OF USE
Phexxi is not effective for the prevention of pregnancy when administered after intercourse.
IMPORTANT SAFETY INFORMATION
What are the possible side effects of Phexxi?
There have been a few cases of urinary bladder infection and kidney infection reported in clinical studies. One of the cases was serious. Avoid Phexxi if you have had repeated urinary tract infections or other urinary tract problems.
The most common side effects were vaginal burning, vaginal itching, vaginal yeast infection, urinary tract infection, vaginal area discomfort, bacterial vaginosis, and vaginal discharge. Women also reported genital discomfort, pain while urinating, and vaginal pain. Some male partners reported genital discomfort.
What else should I know about using Phexxi?
Phexxi does not protect against any sexually transmitted diseases, including HIV. Avoid using Phexxi with a vaginal ring.
Contact your healthcare provider if you are experiencing severe genital irritation or discomfort or urinary tract symptoms. Avoid Phexxi if you or your sexual partner is allergic to lactic acid, citric acid, potassium bitartrate, or any of the ingredients in Phexxi. Stop using Phexxi if you develop an allergic reaction.
Full Prescribing Information for Phexxi is available at Phexxi.com.
To report SUSPECTED ADVERSE REACTIONS, contact Evofem at toll-free phone 1-833-EVFMBIO or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Recent EVFM News
- Form 8-K - Current report • Edgar (US Regulatory) • 09/25/2024 08:15:29 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 09/23/2024 08:48:16 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/06/2024 08:00:17 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/30/2024 09:04:02 PM
- Form D - Notice of Exempt Offering of Securities • Edgar (US Regulatory) • 08/21/2024 04:11:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/20/2024 08:05:29 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2024 11:05:58 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2024 11:00:25 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/23/2024 08:30:11 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/18/2024 08:35:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/18/2024 08:30:28 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/18/2024 12:15:48 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2024 10:50:31 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/15/2024 10:45:57 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/06/2024 10:14:53 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 07:14:48 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 02:05:13 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/31/2024 09:26:38 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 01/25/2024 09:23:08 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/12/2024 10:13:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/11/2024 09:53:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/12/2023 10:17:03 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/07/2023 09:05:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2023 11:40:26 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/03/2023 08:07:45 PM
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM